ArticleScientific reports2025
Prognostic outcome of extranodal marginal zone B-cell lymphoma: a nationwide cohort.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision-Making.European journal of haematology · 2026Review
- Primary Spinal Marginal Zone Lymphoma Presenting With Spinal Cord Compression: A Case Report.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
We aimed to investigate prognostic determinants of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). We analyzed 11,730 patients captured in the National cancer registry. Kaplan-Meier estimates compared survival by sex, age, and SEER stage, while multivariable Cox models identified mortality determinants. Women represented 54.6% of cases and had better survival than men. Age distribution peaked in the fifth-sixth decades. Survival declined with older age and advanced SEER stage. In multivariable models, male sex (hazard ratio [HR] 2.00, 95% confidence interval [CI] 1.48-2.70), advanced age (HR 33.92, 95% CI 18.23-63.10 for ≥ 80 years), and metastatic disease (HR 2.77, 95% CI 2.03-3.78), diabetes, cardiovascular, and cerebrovascular disease were associated with higher mortality. Conversely, higher household income (HR 0.63, 95% CI 0.45-0.88), physical activity (HR 0.60, 95% CI 0.42-0.86), and higher body mass index (HR 0.95, 95% CI 0.91-0.99) were associated with reduced mortality. Subgroup analyses showed consistently worse outcomes for men across age strata. Comorbidity effects were most pronounced at ages 60-79. Income, physical activity, smoking, and BMI have age-specific survival benefits. In conclusion, prognosis in MALT lymphoma is strongly influenced by sex, age, stage, comorbidities, and lifestyle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.